Logo image
Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial
Journal article   Peer reviewed

Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial

Ira Adams-Chapman, Tarah T Colaizy, Kristi L Watterberg, Heidi M Harmon, Tracy L Nolen, Richard J Olson, Shawn Hirsch, Carol A Cole, C Michael Cotten, William Oh, …
Journal of perinatology, Vol.41(8), pp.2072-2087
03/23/2021
DOI: 10.1038/s41372-021-01018-5
PMCID: PMC8349854
PMID: 33758387
url
https://scholarworks.indianapolis.iu.edu/bitstreams/876af33b-4ba9-46b5-b577-dac0bd40749f/downloadView
Open Access

Abstract

This study evaluates the 24-month follow-up for the NICHD Neonatal Research Network (NRN) Inositol for Retinopathy Trial. Bayley Scales of Infants Development-III and a standardized neurosensory examination were performed in infants enrolled in the main trial. Moderate/severe NDI was defined as BSID-III Cognitive or Motor composite score <85, moderate or severe cerebral palsy, blindness, or hearing loss that prevents communication despite amplification were assessed. Primary outcome was determined for 605/638 (95%). The mean gestational age was 25.8 ± 1.3 weeks and mean birthweight was 805 ± 192 g. Treatment group did not affect the risk for the composite outcome of death or survival with moderate/severe NDI (60% vs 56%, p = 0.40). Treatment group did not affect the risk of death or survival with moderate/severe NDI. Despite early termination, this study represents the largest RCT of extremely preterm infants treated with myo-inositol with neurodevelopmental outcome data.

Details

Metrics

Logo image